Anti-CDKN2A/p14ARF antibody [ARF 4C6/4] (ab11048)


  • Product nameAnti-CDKN2A/p14ARF antibody [ARF 4C6/4]
    See all CDKN2A/p14ARF primary antibodies
  • Description
    Mouse monoclonal [ARF 4C6/4] to CDKN2A/p14ARF
  • Tested applicationsSuitable for: Flow Cyt, ELISA, WB, ICC/IF, IPmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    His-tagged p14ARF protein expressed in bacteria.



Our Abpromise guarantee covers the use of ab11048 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use 0.5µg for 106 cells. ab170191-Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
ELISA Use at an assay dependent concentration.
WB Use at an assay dependent concentration. Predicted molecular weight: 14 kDa.
ICC/IF Use at an assay dependent concentration.
IP Use at an assay dependent concentration.


  • RelevanceThe gene for CDK2NA generates several transcripts/proteins which differ from each other in their first exons. Three of these transcripts are generated by alternative splicing (isoform 1 a.k.a p16INK4A, isoform 2 and isoform 3 a.k.a p12), two of which are known to function as inhibitors of CDK4 kinase. One other transcript that is generated from this gene contains an alternate reading frame (ARF), with the first exon located 20kb upstream of the remainder of the gene(isoform 4 a.k.a. p14ARF, p19ARF, ARF). In spite of the structural and some functional differences, all the proteins encoded by the CDKN2A gene are involved in cell cycle G1 control.
  • Cellular localizationCytoplasmic and Nuclear
  • Database links
  • Alternative names
    • ARF antibody
    • CDK4 inhibitor p16 INK4 antibody
    • CDK4I antibody
    • CDKN2 antibody
    • CDKN2A antibody
    • Cell cycle negative regulator beta antibody
    • CMM2 antibody
    • Cyclin dependent kinase 4 inhibitor A antibody
    • Cyclin dependent kinase inhibitor 2A antibody
    • INK4 antibody
    • INK4a antibody
    • Melanoma p16 inhibits CDK4 antibody
    • MLM antibody
    • MTS 1 antibody
    • MTS1 antibody
    • Multiple tumor suppressor 1 antibody
    • p14 antibody
    • p16 antibody
    • p16 INK4a antibody
    • p16INK4a antibody
    • p19 antibody
    • P19ARF antibody
    • TP16 antibody
    see all

Anti-CDKN2A/p14ARF antibody [ARF 4C6/4] images

  • ICC/IF image of ab11048 stained human MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1% BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab11048, 1 µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue). This antibody also gave a positive IF result in HeLa, Hek293 and HepG2cells.
  • Overlay histogram showing HeLa cells stained with ab11048 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab11048, 0.5µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG2a [ICIGG2A] (ab91361, 1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.

References for Anti-CDKN2A/p14ARF antibody [ARF 4C6/4] (ab11048)

This product has been referenced in:
  • Ma H & Pederson T Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway. Mol Biol Cell 18:2630-5 (2007). WB, ICC/IF ; Human . Read more (PubMed: 17494866) »
  • Clark PA  et al. Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2. Oncogene 21:4498-507 (2002). Read more (PubMed: 12085228) »

See all 3 Publications for this product

Product Wall

Thank you for contacting us.

To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below;


Read More

Thank you for contacting Abcam Technical Team and for taking the time to provide some useful details of the experiments. I am very sorry to hear that your customer is having problems with this product. According to Swiss-Prot, the localization o...

Read More

Thank you for your enquiry. Our source for this antibody has told me that ab11048 does detect endogenous p14ARF; please see the following publication for additional information: Llanos S et al. Stabilization of p53 by p14ARF without relocation of MD...

Read More

Thank you for the information about the paper, if you have any more questions, just let us know.

Thank you for your enquiry. Although I was unable to find out exactly what the originator used as a positive control, they have said that Hela cells should be appropriate to use as a positive control for this antibody. If you have any more questions, p...

Read More